Long-term pegvisomant therapy for acromegaly can lead to a sustained increase in adiposity but no change in skeletal muscle mass, according to a study recently published in Journal of the Endocrine Society. Researchers led by Pamela U. Freda, MD, of the Columbia University Department of Medicine in New York, point out that pegvisomant, a growth […]
Study Examines Body-Composition Changes with Long-Term Pegvisomant Therapy of Acromegaly
Join the Global Movement Advancing Endocrine Science and Medicine
Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.